Financial Results
Sharda Cropchem Reports Strong Q2 FY27 Growth
Sharda Cropchem reported Q2 FY27 consolidated revenue growth of 13% to Rs. 1,052 crore and EBITDA growth of 18% to Rs. 164 crore, while maintaining 10–15% FY27 revenue guidance.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
5
Neutral
6
Bullish
3
Bearish
33
Neutral
6
Bullish
7
Bearish
28
Neutral
0
Bullish
4
Bearish
28
Neutral
0
Bullish
4
Bearish
28
Neutral
0
Bullish
4
Bearish
28
Neutral
0
Bullish
4
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone

Fertilizers & Agrochemicals
Pesticides & Agrochemicals
6,034 Cr
High Risk
9.6
18.4
1.3
2.0
1,297.80
628.00
Sales CAGR
Profit CAGR
ROE
ROCE
Sharda Cropchem Ltd (SHARDACROP) is currently trading at 668.85 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Sharda Cropchem Limited is an intellectual-property-led agrochemical company marketing and distributing crop protection formulations and generic active ingredients, alongside non-agrochemical products including conveyor belts, dyes, dye intermediates and industrial chemicals across more than 80 countries. The company combines 3,044 registrations, over 525 distributors and more than 500 sales professionals with an asset-light partner-manufacturing model, allowing it to control regulatory assets and customer access without owning significant manufacturing infrastructure. H1 FY27 revenue rose 11% to Rs. 2,125.5 crore, while EBITDA increased 22% to Rs. 342.9 crore and margin expanded 140 basis points to 16.1%, demonstrating operating leverage despite uneven regional agrochemical performance. Growth is increasingly diversified beyond Europe: H1 agrochemical revenue declined 9% in Europe but increased 21% in NAFTA and 69% in Latin America, while non-agrochemical revenue grew 40% overall, led by particularly strong NAFTA performance. Balance-sheet quality remains a notable strength, with no borrowings, Rs. 846 crore of cash, bank balances and liquid investments, and working-capital days improving from 98 to 70 between March and September 2026.
Over the past 52 weeks, Sharda Cropchem Ltd has traded between a low of ₹628.00 and a high of ₹1,297.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Sharda Cropchem Ltd has a market capitalization of approximately 6,166.12. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Sharda Cropchem Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 9.85 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 6,166.12 Cr, Sharda Cropchem Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Sharda Cropchem Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Sharda Cropchem Ltd is 9.85. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
SCL reports 3,044 registrations. It describes those registrations, together with dossiers and intellectual-property rights, as regulatory assets supporting access to crop-protection markets.
Sharda Cropchem recorded a 19.7% EBITDA margin in FY26. This was higher than 14.2% in FY25 and 10.1% in FY24, while remaining below the 20.4% level reported in FY22.
SC reported working-capital days of 70 at September 2026, down from 98 at March 2026. Receivable days fell by 61 days to 90, exceeding the 26-day increase in inventory days and the seven-day fall in creditor days.
Sharda Cropchem reported PAT of Rs 179.7 crore in H1 FY27, down 17% from Rs 217.2 crore in H1 FY26. Its foreign-exchange gain was Rs 7.2 crore, compared with Rs 67 crore in the previous-year half, while depreciation and amortisation increased to Rs 200.6 crore from Rs 154.3 crore.
Financial Results
Sharda Cropchem reported Q2 FY27 consolidated revenue growth of 13% to Rs. 1,052 crore and EBITDA growth of 18% to Rs. 164 crore, while maintaining 10–15% FY27 revenue guidance.
Investor Presentation
Sharda Cropchem submitted its investor presentation for the quarter and half year ended 30 September 2026, outlining its global agrochemical platform, business model and growth strategy.
Financial Results
Sharda Cropchem approved unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026.
Earnings Call/Transcript
Sharda Cropchem will hold a post-results conference call for analysts and investors on 2 November 2026 at 3:00 PM IST to discuss 2QFY27 earnings.
